Do analysts prefer AADI or PRLD?

Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 40.42%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Prelude Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts rate QTTB or AADI?

Q32 Bio presently has a consensus price target of $31.00, suggesting a potential upside of 158.55%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Q32 Bio is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, QTTB or AADI?

Q32 Bio has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 6.64 $29.82M $3.00 4.00 Aadi Bioscience $25.07M 4.53 -$65.76M -$2.35 N/A

Is QTTB or AADI more profitable?

Q32 Bio has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Q32 Bio's return on equity of 50.17% beat Aadi Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Aadi Bioscience -246.06% -71.87% -57.28%

Do analysts recommend AADI or CMPX?

Compass Therapeutics has a consensus target price of $11.77, suggesting a potential upside of 394.51%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Compass Therapeutics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88

Do analysts recommend AADI or PRTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, AADI or PRTC?

Aadi Bioscience has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07M 4.53 -$65.76M -$2.35 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Do analysts recommend EPRX or AADI?

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, suggesting a potential upside of 114.29%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Aadi Bioscience (AADI) Competitors

$4.60 -0.03 (-0.65%)

As of 09/4/2026

Compare

AADI vs. PRLD, QTTB, CMPX, PRTC, and EPRX

Should you buy Aadi Bioscience stock or one of its competitors? Aadi Bioscience's main competitors and comparable companies include Prelude Therapeutics (PRLD), Q32 Bio (QTTB), Compass Therapeutics (CMPX), PureTech Health (PRTC), and Eupraxia Pharmaceuticals (EPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aadi Bioscience compare to Prelude Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prelude Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 40.42%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Aadi Bioscience has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A
Prelude Therapeutics	$22.42M	19.43	-$99.50M	-$0.73	N/A

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, Prelude Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Prelude Therapeutics' score of -0.17 indicating that Aadi Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Prelude Therapeutics	Neutral

Summary

Prelude Therapeutics beats Aadi Bioscience on 11 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Q32 Bio presently has a consensus price target of $31.00, suggesting a potential upside of 158.55%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Q32 Bio is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Q32 Bio has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Q32 Bio's return on equity of 50.17% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Q32 Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	6.64	$29.82M	$3.00	4.00
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A

In the previous week, Q32 Bio had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Q32 Bio and 0 mentions for Aadi Bioscience. Q32 Bio's average media sentiment score of 1.22 beat Aadi Bioscience's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Q32 Bio	Positive
Aadi Bioscience	Neutral

Summary

Q32 Bio beats Aadi Bioscience on 13 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Compass Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Compass Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Compass Therapeutics and 0 mentions for Aadi Bioscience. Compass Therapeutics' average media sentiment score of 1.63 beat Aadi Bioscience's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Compass Therapeutics	Very Positive

Compass Therapeutics has a consensus target price of $11.77, suggesting a potential upside of 394.51%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compass Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Compass Therapeutics' return on equity of -38.71% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Compass Therapeutics	N/A	-38.71%	-34.72%

Aadi Bioscience has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A
Compass Therapeutics	$850K	504.25	-$66.49M	-$0.40	N/A

Summary

Compass Therapeutics beats Aadi Bioscience on 13 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to PureTech Health?

Aadi Bioscience (NASDAQ:AADI) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

PureTech Health has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. PureTech Health's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
PureTech Health	N/A	N/A	N/A

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aadi Bioscience has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
PureTech Health	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Summary

PureTech Health beats Aadi Bioscience on 6 of the 10 factors compared between the two stocks.

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Eupraxia Pharmaceuticals' return on equity of -63.97% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, suggesting a potential upside of 114.29%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A

In the previous week, Eupraxia Pharmaceuticals had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Eupraxia Pharmaceuticals and 0 mentions for Aadi Bioscience. Eupraxia Pharmaceuticals' average media sentiment score of 1.06 beat Aadi Bioscience's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Positive
Aadi Bioscience	Neutral

Eupraxia Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.61M	$4.03B	$7.27B	$12.91B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-2.02	12.71	273.83	25.45
Price / Sales	4.53	1,311.23	610.26	80.13
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	1.07	16.15	12.85	6.17
Net Income	-$65.76M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-0.43%	0.31%	1.04%	-0.14%
1 Month Performance	11.11%	8.25%	5.52%	1.02%
1 Year Performance	154.14%	49.17%	24.39%	14.51%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.60 -0.6%	N/A	+155.8%	$113.61M	$25.07M	N/A	40
PRLD Prelude Therapeutics	1.72 of 5 stars	$5.49 -2.0%	$7.67 +39.6%	+378.9%	$446.90M	$12.14M	N/A	120
QTTB Q32 Bio	3.5657 of 5 stars	$14.36 -3.4%	$31.00 +115.9%	+622.3%	$442.67M	$53.74M	4.79	39	Positive News
CMPX Compass Therapeutics	2.688 of 5 stars	$2.31 -3.3%	$11.77 +409.5%	-29.4%	$430.41M	$850K	N/A	20	News Coverage Positive News
PRTC PureTech Health	0.0034 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. PRLD, QTTB, CMPX, PRTC, and EPRX

How does Aadi Bioscience compare to Prelude Therapeutics?

Summary

How does Aadi Bioscience compare to Q32 Bio?

Summary

How does Aadi Bioscience compare to Compass Therapeutics?

Summary

How does Aadi Bioscience compare to PureTech Health?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. PRLD, QTTB, CMPX, PRTC, and EPRX

How does Aadi Bioscience compare to Prelude Therapeutics?

Do insiders & institutionals hold more shares of AADI or PRLD?

Is AADI or PRLD more profitable?

Do analysts prefer AADI or PRLD?

Which has stronger earnings and valuation, AADI or PRLD?

Which has more volatility & risk, AADI or PRLD?

Does the media favor AADI or PRLD?

Summary

How does Aadi Bioscience compare to Q32 Bio?

Do analysts rate QTTB or AADI?

Do insiders and institutionals have more ownership in QTTB or AADI?

Is QTTB or AADI more profitable?

Which has more volatility & risk, QTTB or AADI?

Which has better valuation & earnings, QTTB or AADI?

Does the media favor QTTB or AADI?

Summary

How does Aadi Bioscience compare to Compass Therapeutics?

Does the media favor AADI or CMPX?

Do analysts recommend AADI or CMPX?

Which has more risk and volatility, AADI or CMPX?

Do insiders & institutionals have more ownership in AADI or CMPX?

Is AADI or CMPX more profitable?

Which has higher earnings and valuation, AADI or CMPX?

Summary

How does Aadi Bioscience compare to PureTech Health?

Is AADI or PRTC more profitable?

Do insiders & institutionals believe in AADI or PRTC?

Which has better valuation and earnings, AADI or PRTC?

Does the media favor AADI or PRTC?

Do analysts recommend AADI or PRTC?

Which has more risk and volatility, AADI or PRTC?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Do institutionals and insiders hold more shares of EPRX or AADI?

Is EPRX or AADI more profitable?

Do analysts recommend EPRX or AADI?

Which has stronger earnings & valuation, EPRX or AADI?

Does the media prefer EPRX or AADI?

Which has more volatility and risk, EPRX or AADI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools